Jan 20 (Reuters) - Novavax ‌said on Tuesday it signed a licensing ‌agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for use in up to two infectious diseases, ...

The vaccine against COVID-19 being developed and tested by Novavax has been accepted for rolling review by the European Medicines Agency (EMA). The vaccine, NVX-CoV2372, is in Phase 3 clinical trials ...

Novavax posted Q1 revenue of $139.5 million, above analysts’ estimate of $78.3 million, helped by licensing agreements. ・The drugmaker also said that patients who received Nuvaxovid were “twice as ...

Novavax raised its adjusted revenue forecast for 2026 on Thursday, banking on milestone payments from licensing and supply deals for its shots, although it noted that the current regulatory ...

In early May 2026, Novavax reported first-quarter revenue of US$139.51 million versus US$666.66 million a year earlier, swinging from net income of US$518.65 million to a net loss of US$9.49 million ...

Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is ...

By Michael Erman and Siddhi Mahatole May 6 (Reuters) - Novavax on Wednesday beat Wall Street estimates for first-quarter revenue, as milestone payments from vaccine supply and licensing deals helped ...

CNN — Novavax on Monday announced the start of the Phase 3 trial of its Covid-19 vaccine in the United States and Mexico. It is the fifth company to launch a large-scale trial of a coronavirus vaccine ...

Novavax’s share price is down 41% year-to-date, bringing its six-month decline to 65%. The prospects of the biopharmaceutical company bringing a vaccine against Covid-19 to market in the U.S. grow ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The deal would funnel crucial ...